Encore Medical now private:
This article was originally published in Clinica
Executive Summary
Encore Medical's shares have ceased trading on Nasdaq after the company completed a buy-out backed by private equity group Blackstone Capital Partners. The $887m transaction, announced in June (see Clinica No 1213, p 15), was approved on November 2 at a special meeting of stockholders, who will receive $6.55 cash per share of common stock held. The deal was financed by equity contributed by Blackstone, cash on hand, credit facilities and new notes. Blackstone director Chinh Chu becomes chairman of the Austin, Texas-based orthopaedic device maker.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.